We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Direct Sequencing Measures Mutation Rate in Humans

By LabMedica International staff writers
Posted on 10 Sep 2009
Print article
An international team of 16 scientists reported the first direct measurement of the general rate of genetic mutation at individual DNA letters in humans. The team sequenced the same piece of DNA--10,000,000 or so letters (nucleotides) from the Y chromosome--from two men separated by 13 generations, and counted the number of differences. Among all these nucleotides, they found only four mutations.

In 1935, one of the founders of modern genetics, J. B. S. Haldane, studied men in London (UK) with the blood disease hemophilia and estimated that there would be one in 50,000 incidence of mutations causing hemophilia in the gene affected--the equivalent of a mutation rate of possibly one in 25 million nucleotides across the genome. Others have measured rates at a few additional specific genes or compared DNA from humans and chimpanzees to produce general estimates of the mutation rate expressed more directly in nucleotides of DNA.

Extraordinarily, the new research, published in the August 27, 2009, issue of the journal Current Biology, revealed that these early estimates were correct--in total, humans all carry 100-200 new mutations in their DNA. This is equivalent to one mutation in each 15-30 million nucleotides. Fortunately, most of these are harmless and have no apparent effect on one's health or appearance. "The amount of data we generated would have been unimaginable just a few years ago,” said Dr. Yali Xue, from the Wellcome Trust Sanger Institute (Cambridge, UK), and one of the project's leaders. "But finding this tiny number of mutations was more difficult than finding an ant's egg in the emperor's rice store.”

Team member Qiuju Wang recruited a family from China who had lived in the same village for centuries. The team studied two distant male-line relatives--separated by thirteen generations--whose common ancestor lived 200 years ago. To establish the rate of mutation, the team examined an area of the Y chromosome. The Y chromosome is unique in that, apart from rare mutations, it is passed unchanged from father to son, so mutations accumulate slowly over the generations. Despite many generations of separation, researchers discovered only 12 differences among all the DNA letters examined. The two Y-chromosomes were still identical at 10,149,073 of the 10,149,085 letters examined. Of the 12 differences, eight had arisen in the cell lines used for the work. Only four were true mutations that had occurred naturally through the generations.
Scientists have known for a long time that mutations occur occasionally in each human being, but have had to guess precisely how often. Now, because advances in the technology for reading DNA, this new research has been possible, according to the investigators.

Understanding mutation rates is key to many aspects of human evolution and medical research: mutation is the ultimate source of all genetic variation and provides a molecular clock for measuring evolutionary timescales. Mutations can also lead directly to diseases such as cancer. With better measurements of mutation rates, scientists could improve the calibration of the evolutionary clock, or test ways to reduce mutations, for example.

Even with the latest DNA sequencing technology, the researchers had to design a special strategy to search for the vanishingly rare mutations. They used next-generation sequencing to establish the order of letters on the two Y-chromosomes and then compared these to the Y chromosome reference sequence.

Having identified 23 candidate single nucleotide polymorphisms (SNPs)--or single letter changes in the DNA--the investigators amplified the regions containing these candidates and checked the sequences using the standard Sanger method. Four naturally occurring mutations were confirmed. Knowing this number of mutations, the length of the area that they had searched, and the number of generations separating the individuals, the team was able to calculate the rate of mutation.

"These four mutations gave us the exact mutation rate--one in 30 million nucleotides each generation--that we had expected,” stated the study's coordinator, Chris Tyler-Smith, also from The Wellcome Trust Sanger Institute. "This was reassuring because the methods we used--harnessing next-generation sequencing technology--had not previously been tested for this kind of research. New mutations are responsible for an array of genetic diseases. The ability to reliably measure rates of DNA mutation means we can begin to ask how mutation rates vary between different regions of the genome and perhaps also between different individuals.”

Participating Centers involved in the project include: The Wellcome Trust Sanger Institute (Hinxton, Cambridgeshire, UK); Chinese People's Liberation Army General Hospital (Beijing, China); and Beijing Genomics Institute at Shenzhen (China).

Related Links:

Wellcome Trust Sanger Institute


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.